Patients

Named patient programs enable controlled access to medicines that are either investigational or approved but not yet available in a patient’s home country. Requirements for these programs vary by country.

At this time, Ascendis has one active Named Patient Program:

Hypoparathyroidism in Adults

European Union, Switzerland, UK and Norway
Ascendis currently offers a Named Patient Program (NPP) for eligible adult patients with chronic hypoparathyroidism who live in European Union member countries, Switzerland, UK, or Norway.

Request Process
The decision to seek access for treatment through the NPP for adults with chronic hypoparathyroidism in the European Union, Switzerland, UK, and Norway must be made by the patient’s physician, who will have sole responsibility and accountability for the clinical management and treatment of the patient. Please note that submitting a request does not guarantee that the request will be granted.

Physicians in these countries who have questions or who wish to make a request for an eligible patient should contact [email protected].

Response
We aim to have a response back within 10 business days after receiving the request.

Please continue to check our website for updates to this NPP program and process.